Palatin Technologies News - PTN

Company Name	Stock Ticker Symbol	Market	Type
Palatin Technologies Inc New	PTN	AMEX	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	0.00	0.0%	2.36	07:00:00

Open Price	Low Price	High Price	Close Price	Prev Close
				2.36

more quote information »

Recent News

Date	Time	Source	Heading
12/04/2023	17:00	EDGAR2	Form S-1 - General form for registration of securities under..
12/01/2023	15:52	EDGAR2	Form 144 - Report of proposed sale of securities
11/14/2023	07:30	PRNUS	Palatin Reports First Quarter Fiscal Year 2024 Financial..
11/09/2023	07:30	PRNUS	Palatin to Report First Quarter Fiscal Year 2024 Results;..
10/24/2023	16:50	PRNUS	Palatin Announces Closing of $5 Million Registered Direct..
10/24/2023	16:05	EDGAR2	Form 8-K - Current report
10/24/2023	14:38	EDGAR2	Form 424B5 - Prospectus [Rule 424(b)(5)]
10/23/2023	07:30	PRNUS	Palatin Announces $5 Million Registered Direct Offering
10/19/2023	08:01	EDGAR2	Form 8-K - Current report
10/19/2023	07:30	PRNUS	Palatin Announces Preliminary Quarter Ended September 30,..
10/18/2023	07:30	PRNUS	Palatin Announces Positive Preclinical Data Showing..
10/16/2023	07:30	PRNUS	Palatin Presents Data at the United European..
10/13/2023	16:31	EDGAR2	Form 8-K - Current report
10/13/2023	16:15	PRNUS	Palatin Receives Notice of Non-Compliance from NYSE American
9/28/2023	08:02	EDGAR2	Form 8-K - Current report
9/28/2023	08:00	EDGAR2	Form 10-K - Annual report [Section 13 and 15(d), not S-K..
9/28/2023	07:30	PRNUS	Palatin Reports Fourth Quarter and Fiscal Year Ended 2023..
9/22/2023	16:00	PRNUS	Palatin to Report Fourth Quarter and Fiscal Year End 2023..
9/08/2023	08:00	EDGAR2	Form 8-K - Current report
9/07/2023	16:00	PRNUS	Palatin to Present at the H.C. Wainwright 25th Annual Global..
9/07/2023	08:49	EDGAR2	Form 8-K - Current report
9/07/2023	07:30	PRNUS	Palatin Completes Enrollment in Phase 3 MELODY-1 Study of..
8/16/2023	21:01	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/16/2023	21:00	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
8/10/2023	08:15	EDGAR2	Form 8-K - Current report
8/10/2023	07:30	PRNUS	Palatin Initiates Clinical Program for Bremelanotide..
8/08/2023	08:00	EDGAR2	Form 8-K - Current report
8/08/2023	07:30	PRNUS	Palatin's Vyleesi® Licensee Fosun Pharma Reports First..
8/07/2023	08:00	EDGAR2	Form 8-K - Current report
8/07/2023	07:30	PRNUS	Palatin Announces Direct-to-Consumer Telehealth Partnership..
8/04/2023	08:00	EDGAR2	Form 8-K - Current report
8/04/2023	07:30	PRNUS	Palatin to Participate in Canaccord Genuity's 43rd Annual..
7/11/2023	08:25	EDGAR2	Form 8-K - Current report
7/11/2023	07:30	PRNUS	Palatin Announces Preliminary Fourth Quarter Fiscal 2023..
5/30/2023	07:30	PRNUS	Palatin Presents Preclinical Diabetic Nephropathy Data at..
5/16/2023	07:30	PRNUS	Palatin Reports Third Quarter Fiscal Year 2023 Financial..
5/11/2023	16:15	PRNUS	Palatin to Report Third Quarter Fiscal Year 2023 Results;..
5/09/2023	07:30	PRNUS	Palatin Presents PL8177 Ulcerative Colitis Data at Digestive..
5/08/2023	16:04	PRNUS	Palatin Invites Investors to Listen to Replay of the PL9643..
5/01/2023	16:00	PRNUS	Palatin Technologies to Host Key Opinion Leader Webinar
4/27/2023	07:30	PRNUS	Palatin Presents Initial Dry Eye Disease Phase 3 Clinical..
4/25/2023	07:30	PRNUS	Palatin Presents Data at the Association of Research in..
4/19/2023	07:30	PRNUS	Palatin Announces Preliminary Third Quarter Fiscal 2023..
4/18/2023	07:30	PRNUS	Pre-Clinical Data of Palatin's Melanocortin Agonist..
3/02/2023	07:30	PRNUS	Frontiers in Immunology Publishes Pre-Clinical Study of..
2/28/2023	07:30	PRNUS	Palatin Issued Patent on Vyleesi® (Bremelanotide Injection)..
2/15/2023	07:30	PRNUS	Palatin Reports Second Quarter Fiscal Year 2023 Financial..
2/10/2023	07:30	PRNUS	Palatin to Report Second Quarter Fiscal Year 2023 Results;..
1/19/2023	07:30	PRNUS	Palatin Initiates Enrollment in the Phase 2 Bremelanotide..
1/18/2023	07:30	PRNUS	Palatin Receives $4.7 Million of Non-Dilutive Funding